AllianceBernstein’s Galectin Therapeutics GALT Stock Holding History

AllianceBernstein’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$31.2K	Buy	+11,200	New	+$29K	﹤0.01%	3309
2021 Q2	–	Sell	-12,400	Closed	-$27K	–	3356
2021 Q1	$27K	Hold	12,400	–	–	﹤0.01%	3211
2020 Q4	$28K	Sell	12,400 -1,600	-11%	-$4.2K	﹤0.01%	3155
2020 Q3	$37K	Sell	14,000 -1,900	-12%	-$5.32K	﹤0.01%	3133
2020 Q2	$49K	Buy	+15,900	New	+$40K	﹤0.01%	3161
2015 Q2	–	Sell	-2,000	Closed	-$7K	–	3106
2015 Q1	$7K	Sell	2,000 -200	-9%	-$714	﹤0.01%	3386
2014 Q4	$8K	Sell	2,200 -1,800	-45%	-$7.96K	﹤0.01%	3329
2014 Q3	$20K	Hold	4,000	–	–	﹤0.01%	3204
2014 Q2	$55K	Buy	4,000 +3,587	+869%	+$44.7K	﹤0.01%	3098
2014 Q1	$6K	Buy	413 +200	+94%	+$2.85K	﹤0.01%	3324
2013 Q4	$2K	Hold	213	–	–	﹤0.01%	3228
2013 Q3	$2K	Buy	+213	New	+$1.44K	﹤0.01%	3239

Other funds holding GALT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

AllianceBernstein's GALT Position: Q2 2026 in Review

AllianceBernstein opened a new position in Galectin Therapeutics (GALT) in Q2 2026: 11,200 shares worth $31.2K. The stake represents ﹤0.01% of the portfolio and ranks #3309 among its holdings. This is a return to the name: AllianceBernstein previously reported a position in GALT as recently as Q1 2021.

AllianceBernstein first reported a position in GALT in Q3 2013 and has held it in 12 quarters since. The position peaked at $55K in Q2 2014. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

AllianceBernstein held 11,200 shares of Galectin Therapeutics worth $31.2K as of Q2 2026.
Galectin Therapeutics was a new AllianceBernstein position in Q2 2026.
Galectin Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #3309 holding.
AllianceBernstein first reported a position in Galectin Therapeutics in Q3 2013 and has held it in 12 quarters since.
AllianceBernstein's Galectin Therapeutics position peaked at $55K in Q2 2014.
98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.